Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 2/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 3/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP14 | P50281 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18685345 | 0.81 | METAP2 (0.36) | MMP2MMP3ADRB2CNR2CNR1 | |
| SCHEMBL11951548 | 0.80 | GLP1R (0.49) | GLP1RMMP2MMP9MMP14MMP3 | |
| SCHEMBL18461189 | 0.78 | GAA (0.52) | MMP2MMP9MMP14MMP3CA2 | |
| SCHEMBL6822328 | 0.78 | CRBN (0.53) | TP53MCOLN3CRBNCA2 | |
| SCHEMBL16232116 | 0.77 | GAA (0.55) | ADRB2CNR1CA2 | |
| SCHEMBL18440551 | 0.77 | GAA (0.55) | ADRB2CNR1CA2 | |
| SCHEMBL30025785 | 0.77 | GLP1R (0.41) | AOC2GLP1RMMP2MMP9MMP14 | |
| SCHEMBL18461186 | 0.76 | MMP2 (0.62) | AOC2MMP2MMP9MMP14MMP3 | |
| SCHEMBL10228581 | 0.76 | ALDH1A1 (0.53) | TP53CNR2CNR1KCNH2CRBN | |
| SCHEMBL30026793 | 0.75 | EPHX1 (0.47) | AOC2GLP1RMMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | AOC2 1743/4885GLP1R 1869/4885MMP2 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.